In patients with high-risk early-stage ERBB2-negative breast cancer, adding cemiplimab plus fianlimab to neoadjuvant chemotherapy gave estimated pCR rates of 44% (n=78) vs 21% in 350 controls, graduating in all subtypes; 21% developed adrenal insufficiency.
RCTn = 428
Isaacs et al. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial